FDA Determines Regulatory Review Period for GORE CARDIOFORM ASD OCCLUDER Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the GORE CARDIOFORM ASD OCCLUDER medical device patent extension, as required by law, following a submission to the U.S. Patent and Trademark Office (USPTO).